Skip to the main content

Croatian Medical Journal, Vol. 61 No. 3, 2020.

Original scientific paper

https://doi.org/10.3325/cmj.2020.61.93

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study

Zrinka Bukvić Mokos ; Department of Dermatovenereology, University Hospital Center Zagreb, Zagreb,Croatia
Mikela Petković ; Department of Dermatovenereology, University Hospital Center Zagreb, Zagreb,Croatia
Anamaria Balić ; Department of Dermatovenereology, University Hospital Center Zagreb, Zagreb,Croatia
Branka Marinović ; Department of Dermatovenereology, University Hospital Center Zagreb, Zagreb,Croatia

Full text: english pdf 272 Kb

page 93-99

downloads: 295

cite

Abstract

Aim To evaluate the association between the use of dipep-
tidyl peptidase-4 inhibitors (DPP4I) and clinical and labora-
tory findings of bullous pemphigoid (BP) in patients treat-
ed at the European Reference Network – Skin Reference
Centre in Croatia.
Methods This retrospective study enrolled 82 patients
treated for BP at the Department of Dermatovenereology,
University Hospital Center Zagreb from January 2015 to
December 2019. Clinical features of BP, presence of comor-
bidities, and laboratory findings of anti-BP antibodies and
eosinophilia were analyzed in three groups of BP patients:
1) diabetes mellitus (DM) type II patients treated with DP-
P4I, 2) DM type II patients not treated with DPP4I, and 3)
non-DM type II patients.
Results The average age and anti-BP180 titer were similar
in all three groups. DPP4I group had a slightly lower eo-
sinophil level in both peripheral blood (4.89%) and biopsy
specimens (87.5%), but the difference was not significant.
The prevalence of inflammatory BP in DPP4I group was
76.5%. DPP4I group had significantly higher percentage
of patients with chronic renal failure and dementia (52.9%
and 11.8%, respectively) compared with non-DPP4I DM
(14.3% and 0%, respectively) and non-DM type II patients
(15.7% and 0%, respectively).
Conclusion BP patients treated with DPP4I and those not
treated with DPP4Is did not significantly differ in laborato-
ry findings. However, DPP4I treatment was associated with
an inflammatory subtype of BP and a higher prevalence of
dementia and chronic renal failure. These findings warrant
further research into the association of BP and DM with de-
mentia and chronic renal failure.

Keywords

Hrčak ID:

253120

URI

https://hrcak.srce.hr/253120

Publication date:

14.6.2020.

Visits: 782 *